Showing results (121-130 of 144) with videos related to

Sort By:
Pageof 15
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 1, 2023
Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapySilvia Guil-Luna, Aurora Rivas-Crespo, Carmen Navarrete-Sirvent, et al.
Drugs & Aging|February 22, 2021
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled AnalysisPilar García-Alfonso, Eduardo Díaz-Rubio, Albert Abad, et al.
Clinical Colorectal Cancer|April 13, 2020
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively CollectedJavier Sastre, Virginia de la Orden, Antonio Martínez, et al.
Molecular Cancer Therapeutics|June 20, 2017
Optimization of <i>RAS/BRAF</i> Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal CancerCristina Santos, Daniel Azuara, Rocio Garcia-Carbonero, et al.
Journal of Neuro-Oncology|March 28, 2024
A new updated prognostic index for patients with brain metastases (BMs) treated with palliative whole brain radiotherapy (WBRT) in the era of precision oncology. METASNCore projectPablo Flores-Paco, Alicia Vargas-Aliaga, María Geraldina Guevara, et al.
The Journal of Pathology|April 5, 2023
Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancerRafael Mena-Osuna, Ana Mantrana, Silvia Guil-Luna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2022
Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B StudyJoana Vidal, Maria Concepción Fernández-Rodríguez, David Casadevall, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 24, 2005
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD)Joan Maurel Santasusana, José Luis García López, Juan José García, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial)Guillem Argilés, Nuria Mulet, Manuel Valladares-Ayerbes, et al.
Cancers|September 28, 2021
Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS StudyPilar García-Alfonso, Andrés Muñoz, Jerónimo Jiménez-Castro, et al.
Pageof 15